Phase I clinical study of brentuximab vedotin (SGN-35) involving children with recurrent or refractory CD30-positive Hodgkin’s lymphoma or systemic anaplastic large cell lymphoma: rationale, design and methods of BV-HLALCL study: study protocol

Phase I clinical study of brentuximab vedotin (SGN-35) involving children with recurrent or refractory CD30-positive Hodgkin’s lymphoma or systemic anaplastic large cell lymphoma: rationale, design and methods of BV-HLALCL study: study protocol

Abstract Background Hodgkin’s lymphoma (HL) and anaplastic large-cell lymphoma (ALCL) are the two most common tumors expressing CD30. Internationally, a clinical study that is being conducted involving adults with recurrent or refractory HL or ALCL suggests efficacy of brentuximab vedotin (SGN-35)....

Full description

Bibliographic Details
Main Authors: Masahiro Sekimizu, Akihiro Iguchi, Tetsuya Mori, Yuhki Koga, Akiko Kada, Akiko M. Saito, Keizo Horibe
Format: Article
Language:English
Published: BMC 2018-02-01
Series:BMC Cancer
Subjects:
Brentuximab vedotin
SGN-35
Children
Hodgkin’s lymphoma
Anaplastic large cell lymphoma
Online Access:http://link.springer.com/article/10.1186/s12885-018-4042-1

Internet

http://link.springer.com/article/10.1186/s12885-018-4042-1

Similar Items